In an interview on CNBC's Mad Money, Greg Hayes said the company's backlog of about $150B gives him confidence in the near term. He is "highly confident" in the technology the company can bring to bear. Hayes said traffic is about 70% back on the commercial aerospace side. "We knew we would be a cash generating machine once we integrated the businesses," he added. His goal is to get rid of 25% of the office space across the company. He plans to give employees flexibility on working from home once the pandemic ends.

The company states: "Glaukos announced that it has entered into a new development and commercialization license agreement with Santen Pharmaceutical for the PRESERFLO MicroShunt, superseding the previous collaboration and distribution agreements between the two parties. Under the new agreement, Glaukos obtains exclusive commercialization rights for the MicroShunt in the United States, Australia, New Zealand, Canada, Brazil, Mexico and the remainder of Latin America. The new agreement also provides Glaukos with full control over all development activities for the MicroShunt in these same territories, including over all clinical development and regulatory affairs activities in the United States following a transition period. Santen submitted a premarket approval application to the FDA in June 2020 and discussions with the FDA remain ongoing."

In a regulatory filing, Cable One disclosed that its CFO Steven Cochran bought 600 shares of common stock on May 14th in a total transaction size of $1.34M.